42.17
42.17 (0%)
As of Apr 28, 2025
Akero Therapeutics, Inc. [AKRO]
Source:
Company Overview
Akero Therapeutics, Inc. is a clinical-stage company dedicated to developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis, or MASH, formerly known as non-alcoholic steatohepatitis, or NASH.
| Country | United States |
| Headquarters | south san francisco, california |
| Phone Number | 650-487-6488 |
| Industry | manufacturing |
| CEO | Andrew Cheng |
| Website | www.akerotx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-285.4 |
| Net Income | $-252.1 |
| Net Cash | $106 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -35.9% |
| Profit as % of Stockholder Equity | -33.6% |
Management Effectiveness
| Return on Equity | -33.6% |
| Return on Assets | -30.5% |
| Turnover Ratio | |
| EBITA | $-285.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $825.9 |
| Total Liabilities | $75.8 |
| Operating Cash Flow | $-230.1 |
| Investing Cash Flow | $-109.7 |
| Financing Cash Flow | $445.8 |
